CytoDyn Inc. (CYDY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 05-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 100K 200K 300K Q4 '21: 0 Q1 '22: 41K Q2 '22: 266K Q3 '22: 266K Q4 '22: 266K Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Gross Profit TTM

0 80K 160K 240K Q4 '22: 213K Q4 '22

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '21: -104.5M Q1 '22: -100.6M Q2 '22: -101.4M Q3 '22: -90M Q4 '22: -145.4M Q1 '23: -133.5M Q2 '23: -131.3M Q3 '23: -115.8M Q4 '23: -40.6M Q1 '24: -35.5M Q2 '24: -15.7M Q3 '24: -15.2M Q4 '24: -18.1M Q1 '25: 9M Q2 '25: 8.7M Q3 '25: 8.1M Q4 '25: 9.7M Q1 '26: -17.7M Q2 '26: -35.7M Q3 '26: -38M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '21: -181.5M Q1 '22: -196M Q2 '22: -200.7M Q3 '22: -196.8M Q4 '22: -210.8M Q1 '23: -186.5M Q2 '23: -172.9M Q3 '23: -145.3M Q4 '23: -79.8M Q1 '24: -70.4M Q2 '24: -53.5M Q3 '24: -51.7M Q4 '24: -49.8M Q1 '25: -19M Q2 '25: -14.2M Q3 '25: -7.1M Q4 '25: 3.7M Q1 '26: -21M Q2 '26: -38.9M Q3 '26: -38.8M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue TTM

0 20K 40K 60K Q4 '22: 53K Q4 '22

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q4 '21: -117.6M Q1 '22: -108.4M Q2 '22: -117.1M Q3 '22: -104.5M Q4 '22: -77.7M Q1 '23: -57.1M Q2 '23: -32.6M Q3 '23: -27.7M Q4 '23: -25.1M Q1 '24: -18.5M Q2 '24: -16.6M Q3 '24: -12.7M Q4 '24: -11M Q1 '25: -1M Q2 '25: -2.1M Q3 '25: -4.8M Q4 '25: -8.8M Q1 '26: -16.7M Q2 '26: -17.4M Q3 '26: -18M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '14: -6.6M Q4 '14: -7.4M Q1 '15: -9.2M Q2 '15: -9.8M Q3 '15: -9.5M Q4 '15: -12M Q4 '17: -26.7M Q3 '19: -47.9M Q4 '19: -50.5M Q1 '20: -56.7M Q2 '20: -46.3M Q3 '20: -49.1M Q4 '20: -68.8M Q1 '21: -94.7M Q2 '21: -108.1M Q3 '21: -114.2M Q4 '21: -117.7M Q1 '22: -108.4M Q2 '22: -117.1M Q3 '22: -104.5M Q4 '14 Q3 '15 Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q2 '21: 577.9M Q3 '21: 577.9K Q1 '22: 632.6M Q2 '22: 662.6M Q3 '22: 695.6M Q1 '23: 787.9M Q2 '23: 813.4M Q3 '23: 832.2M Q1 '24: 923.6M Q2 '24: 959M Q3 '24: 982.2M Q1 '25: 1.2B Q2 '25: 1.2B Q3 '25: 1.2B Q1 '26: 1.3B Q2 '26: 1.3B Q3 '26: 1.3B Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q4 '18: -0.22 Q1 '19: -0.26 Q2 '19: -0.29 Q3 '22: -0.31 Q4 '22: -0.31 Q1 '23: -0.27 Q2 '23: -0.24 Q3 '23: -0.20 Q4 '23: -0.10 Q1 '24: -0.08 Q2 '24: -0.06 Q3 '24: -0.05 Q4 '24: -0.04 Q1 '25: -0.01 Q2 '25: -0.00 Q3 '25: 0.01 Q4 '25: 0.00 Q1 '26: -0.02 Q2 '26: -0.04 Q3 '26: -0.04 Q1 '19 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.